Health News

FDA Approves Anti-Clotting Drug Savaysa
The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
Newer Blood Thinner Gaining Affirmation
Patients with atrial fibrillation, a common heart arrhythmia, have a higher risk of experiencing a stroke or blood clots. Warfarin (Coumadin) has long been the gold standard in treatment. That could be changing.
FDA Delays Blood Thinner Eliquis Again
United States Food and Drug Administration officials today delayed approval of Eliquis ( apixaban ) to prevent stroke or systemic embolism in patients with a common heart arrhythmia for the second time.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
Apixaban Fails to Reduce Blood Clots
An experimental drug designed to aid severely ill patients after hospitalization is not more effective than standard treatments for reducing the risk of blood clots, a study has confirmed.
Preventing Strokes in Arrhythmia Patients
Atrial fibrillation, a common heart arrhythmia, is generally treated with a standard drug warfarin. However, a study suggests a new drug might provide the same treatment, but with a lower risk of stroke and embolism.
Alternative Drug Better Treats Heart Arrhythmia
A medication considered the standard for preventing stroke in heart arrhythmia patients may not be as effective as an anti-clotting drug that also boasts fewer side effects.